Physical losses could partially explain modest carotenoid retention in dried food products from biofortified cassava

Gari, a fermented and dried semolina made from cassava, is one of the most common foods in West Africa. Recently introduced biofortified yellow cassava containing provitamin A carotenoids could help tackle vitamin A deficiency prevalent in those areas. However there are concerns because of the low retention of carotenoids during gari processing compared to other processes (e.g. boiling). The aim of the study was to assess the levels of true retention in trans–β-carotene during gari processing and investigate the causes of low retention. Influence of processing step, processor (3 commercial processors) and variety (TMS 01/ 1371; 01/1368 and 01/1412) were assessed. It was shown that low true retention (46% on average) during gari processing may be explained by not only chemical losses (i.e. due to roasting temperature) but also by physical losses (i.e. due to leaching of carotenoids in discarded liquids): true retention in the liquid lost from grating negatively correlated with true retention retained in the mash (R = -0.914). Moreover, true retention followed the same pattern as lost water at the different processing steps (i.e. for the commercial processors). Variety had a significant influence on true retention, carotenoid content, and trans-cis isomerisation but the processor type had little effect. It is the first time that the importance of physical carotenoid losses was demonstrated during processing of biofortified crops

Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial

Purpose: To assess the safety and efficacy of E10030 (Fovista; Ophthotech, New York, NY), a plateletderived growth factor (PDGF) antagonist, administered in combination with the antievascular endothelial growth factor (VEGF) agent ranibizumab (Lucentis; Roche, Basel, Switzerland) compared with ranibizumab monotherapy in patients with neovascular age-related macular degeneration (nAMD).Design: Phase IIb global, multicenter, randomized, prospective, double-masked, controlled superiority trial.Participants: Four hundred forty-nine patients with treatment-naive nAMD.Methods: Participants were randomized in a 1: 1: 1 ratio to 1 of the following 3 intravitreal treatment groups: E10030 0.3 mg in combination with ranibizumab 0.5 mg, E10030 1.5 mg in combination with ranibizumab 0.5 mg, and sham in combination with ranibizumab 0.5 mg (anti-VEGF monotherapy). Drugs were administered monthly in each of the groups for a total duration of 24 weeks.Main Outcome Measures: The prespecified primary end point was the mean change in visual acuity (VA; Early Treatment Diabetic Retinopathy [ETDRS] letters) from baseline to 24 weeks.Results: No significant safety issues were observed in any treatment group. The E10030 (1.5 mg) combination therapy regimen met the prespecified primary end point of superiority in mean VA gain compared with anti-VEGF monotherapy (10.6 compared with 6.5 ETDRS letters at week 24; P = 0.019). A dose-response relationship was evident at each measured time point commencing at 4 weeks. Visual acuity outcomes favored the E10030 1.5 mg combination therapy group regardless of baseline VA, lesion size, or central subfield thickness on optical coherence tomography. All clinically relevant treatment end points of visual benefit (>= 15 ETDRS letter gain, final VA >= 20/40 or >= 20/25) and visual loss (>= 1 ETDRS line loss, >= 2 ETDRS line loss, final VA >= 20/125 or >= 20/200) favored the E10030 1.5 mg combination group.Conclusions: In this phase IIb clinical trial, a 62% relative benefit from baseline was noted in the E10030 1.5 mg combination therapy group compared with the anti-VEGF monotherapy group. A favorable safety and efficacy profile of E10030 combination therapy for nAMD was evident across multiple clinically relevant end points. This highly powered study provides strong rationale for a confirmatory phase III clinical trial. Ophthalmology 2017; 124: 224-234 (C) 2016 by the American Academy of Ophthalmolog

Abnormal air righting behaviour in the spontaneously hypertensive rat model of ADHD

The spontaneously hypertensive rat (SHR) is the most commonly used model of attention-deficit hyperactivity disorder (ADHD), displaying the main symptoms of the disorder which are responsive to psychostimulant treatments. Research to date has focused on behavioural tests investigating functioning of the striatum or prefrontal cortex in these rats. However, there is now evidence that the superior colliculus, a structure associated with head and eye movements, may also be dysfunctional in ADHD. Therefore, the aim of this study was to investigate whether the SHR demonstrated impairment in collicular-dependent behaviour. To this end, we examined air righting behaviour, which has previously been shown to be modulated in a height-dependent manner reliant on a functional superior colliculus. We assessed SHR, Wistar Kyotos and Wistars on static righting and air righting at 50 and 10 cm drop heights. There were no differences in static righting, indicating that there were no gross motor differences that would confound air righting. Qualitative analysis of video footage of the righting did not reveal any changes previously associated with collicular damage, unique to the SHR. However, the SHR did show impairment in height-dependent modulation of righting in contrast to both control strains, such that the SHR failed to modulate righting latency according to drop height. This failure is indicative of collicular abnormality. Given that many rodent tests of attentional mechanisms involve head and eye orienting, which are heavily dependent on the colliculus, a collicular dysfunction has strong implications for the type of attentional task used in this strain